Radiopharmaceuticals for Molecular Imaging

Yun-Sang Lee
{"title":"Radiopharmaceuticals for Molecular Imaging","authors":"Yun-Sang Lee","doi":"10.2174/1876388X01002010178","DOIUrl":null,"url":null,"abstract":"Radiopharmaceuticals for molecular imaging involve careful consideration of the following two factors: radionuclide selection and specificity to the molecular target. In selecting a radionuclide, the specific decay mode, physical half-life, chemical properties, and method of production must be considered. For proper design of a radiopharmaceutical which targets a specific biological or disease process, structural features, including the size, charge, solubility, lipophilicity, and specific activity of the radiolabeled molecules, must be considered. Other factors, such as the rate of metabolism, plasma protein binding, and non-specific binding in non-target tissues, are also important in optimizing the in vivo behavior of radiolabeled molecules. There are several types of radiopharmaceuticals for molecular imaging that target a number of biochemical processes, such as blood flow or perfusion, metabolism, and specific receptors. With a better understanding of the properties of radiopharmaceuticals, including chemical, physical, and biological properties, radiopharmaceuticals can be properly used for molecular imaging of targets for biological or disease processes.","PeriodicalId":88754,"journal":{"name":"The open nuclear medicine journal","volume":"2 1","pages":"178-185"},"PeriodicalIF":0.0000,"publicationDate":"2010-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"24","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The open nuclear medicine journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1876388X01002010178","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 24

Abstract

Radiopharmaceuticals for molecular imaging involve careful consideration of the following two factors: radionuclide selection and specificity to the molecular target. In selecting a radionuclide, the specific decay mode, physical half-life, chemical properties, and method of production must be considered. For proper design of a radiopharmaceutical which targets a specific biological or disease process, structural features, including the size, charge, solubility, lipophilicity, and specific activity of the radiolabeled molecules, must be considered. Other factors, such as the rate of metabolism, plasma protein binding, and non-specific binding in non-target tissues, are also important in optimizing the in vivo behavior of radiolabeled molecules. There are several types of radiopharmaceuticals for molecular imaging that target a number of biochemical processes, such as blood flow or perfusion, metabolism, and specific receptors. With a better understanding of the properties of radiopharmaceuticals, including chemical, physical, and biological properties, radiopharmaceuticals can be properly used for molecular imaging of targets for biological or disease processes.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
分子成像用放射性药物
用于分子成像的放射性药物需要仔细考虑以下两个因素:放射性核素选择和对分子靶标的特异性。在选择放射性核素时,必须考虑其特定的衰变方式、物理半衰期、化学性质和生产方法。为了正确设计针对特定生物或疾病过程的放射性药物,必须考虑放射性标记分子的结构特征,包括大小、电荷、溶解度、亲脂性和特定活性。其他因素,如代谢速率、血浆蛋白结合和非靶组织的非特异性结合,在优化放射性标记分子的体内行为方面也很重要。有几种类型的放射性药物用于分子成像,针对一些生化过程,如血流或灌注、代谢和特定受体。随着对放射性药物特性的更好理解,包括化学、物理和生物特性,放射性药物可以适当地用于生物或疾病过程目标的分子成像。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Imaging of Pulmonary Tuberculosis with 18F-Fluoro-Deoxy-Glucose and 18F-Ethylcholine Low FDG Metabolic Activity of Loco-Regional Recurrence in ThyroidCancer Patients; Is Iodine-131 has a Potentiality? Spinal Tuberculosis Evaluated by Means of 18F-FDG PET/CT: Pilot Study Differential Diagnosis Between Neurodegenerative Dementia Disorders and Parkinson’s Disease Using 99mTc-HMPAO SPECT 123I-Vascular Endothelial Growth Factor-165 (123I-VEGF165) Scintigraphyfor Visualisation of Extranodal Marginal Zone B-Cell Lymphoma of theMucosa-Associated Lymphoid Tissue (MALT) Type
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1